Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
MP

WKN: A3EGXK | ISIN: SE0020353928 | Ticker: MB8
Tradegate
18.11.26 | 13:38
0,904 Euro
+1,23 % +0,011
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MOBERG PHARMA AB Chart 1 Jahr
5-Tage-Chart
MOBERG PHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,8710,91618.11.
0,8830,90218.11.

Aktuelle News zur MOBERG PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.11.Moberg Pharma AB Q3 Loss Declines1
12.11.Moberg Pharma's Interim report January - September 20262
03.11.Moberg Pharma AB: Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015127STOCKHOLM, November 3, 2026. Moberg Pharma AB (OMX: MOB) today announced that the United States Patent and Trademark Office (USPTO) has granted a patent relating to an improved dosing regimen for MOB-015...
► Artikel lesen
05.10.MOBERG PHARMA AB: New analyses on terbinafine susceptibility and MOB-015 published in Journal of Fungi1
28.09.Moberg Pharma to participate at EADV and CPHI1
MOBERG PHARMA Aktie jetzt für 0€ handeln
23.09.Moberg Pharma's Terclara(MOB-015) launched in Israel1
13.08.Moberg Pharma AB: Moberg Pharma's Interim report January - June 2026259APPROVED TRADEMARK CHANGE IN THE FIRST EUROPEAN COUNTRIES AND LICENSE AGREEMENTS FOR APAC AND CHINA SIX-MONTH PERIOD (JAN-JUN 2026) Net revenue SEK 10.7 million (7.5) EBITDA SEK -5.8 million (-13.1)...
► Artikel lesen
11.08.Moberg Pharma AB: Moberg Pharma strengthens organization ahead of European launch335STOCKHOLM, August 11, 2026. Moberg Pharma AB (OMX: MOB) announces changes to its management team and strengthens the organization ahead of upcoming launches. The management team will be joined by two...
► Artikel lesen
30.06.New number of shares and votes in Moberg Pharma AB (publ)2
18.06.MOBERG PHARMA AB: The board of directors exercises authorizations to issue and repurchase C-shares, and converts class C shares to common shares2
15.06.Moberg Pharma AB: Moberg Pharma reports progress on commercial launch preparations357STOCKHOLM, June 15, 2026. Moberg Pharma AB (publ) announces that the first European countries have approved the rebranding of MOB-015 (Terclara®) to Karo Healthcare AB's brand. The approvals provide...
► Artikel lesen
08.06.Moberg Pharma AB: Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to China567STOCKHOLM, June 8, 2026. Moberg Pharma AB (publ) has entered into a license agreement with Karo Healthcare AB regarding the commercialization of the nail fungus drug MOB-015 (Terclara®) in China through...
► Artikel lesen
21.05.Moberg Pharma AB: Bulletin from Moberg Pharma's AGM on May 21[st], 2026307STOCKHOLM, May 21, 2026. Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") held its Annual General Meeting today. The Annual General Meeting resolved on, among other things, the following. Adoption...
► Artikel lesen
12.05.Moberg Pharma AB: Interim report January - March 2026291LICENSE AGREEMENT FOR AUSTRALIA, NEW ZEALAND, SOUTH KOREA AND TAIWAN FIRST QUARTER (JAN-MAR 2026) Net revenue SEK 4.9 million (3.9) EBITDA SEK -1.5 million (-3.7) Operating profit (EBIT) SEK...
► Artikel lesen
24.04.Moberg Pharma AB: Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to Australia, New Zealand, South Korea and Taiwan622STOCKHOLM, April 24, 2026. Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of the nail fungus treatment MOB-015 (Terclara®)...
► Artikel lesen
17.02.Moberg Pharma AB: Moberg Pharma Year-end report 2025411A BREAKTHROUGH YEAR WITH A CLEAR PATH TO EUROPE THE YEAR (JAN-DEC 2025) Net revenue SEK 13.5 million (9.8) EBITDA SEK -25.7 million (-23.5) Operating profit (EBIT) SEK -27.3 million (-324.8)...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1